These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571 [TBL] [Abstract][Full Text] [Related]
7. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. Martinez-Hernandez E; Sepulveda M; Rostásy K; Höftberger R; Graus F; Harvey RJ; Saiz A; Dalmau J JAMA Neurol; 2015 Feb; 72(2):187-93. PubMed ID: 25506781 [TBL] [Abstract][Full Text] [Related]
8. Etiologies of acute demyelinating optic neuritis: an observational study of 110 patients. Deschamps R; Lecler A; Lamirel C; Aboab J; Gueguen A; Bensa C; Vignal C; Gout O Eur J Neurol; 2017 Jun; 24(6):875-879. PubMed ID: 28477397 [TBL] [Abstract][Full Text] [Related]
9. [The role of myelin oligodendrocyte glycoprotein antibodies for detection of demyelinating optic neuritis]. Wei SH; Zhao Y Zhonghua Yan Ke Za Zhi; 2017 Nov; 53(11):874-877. PubMed ID: 29141393 [TBL] [Abstract][Full Text] [Related]
11. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199 [TBL] [Abstract][Full Text] [Related]
12. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077 [TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis. Tajfirouz DA; Bhatti MT; Chen JJ Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369 [TBL] [Abstract][Full Text] [Related]
14. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. Ducloyer JB; Michel L; Wiertlewski S; Lebranchu P Eur J Ophthalmol; 2019 Mar; 29(2):257-261. PubMed ID: 29972029 [TBL] [Abstract][Full Text] [Related]
16. Clinical and MRI phenotype of children with MOG antibodies. Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801 [TBL] [Abstract][Full Text] [Related]
17. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165 [TBL] [Abstract][Full Text] [Related]
18. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Petzold A; Woodhall M; Khaleeli Z; Tobin WO; Pittock SJ; Weinshenker BG; Vincent A; Waters P; Plant GT J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1021-1026. PubMed ID: 31118222 [TBL] [Abstract][Full Text] [Related]
19. Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India. Ambika S; Balasubramanian M; Theresa L; Veeraputhiran A; Arjundas D Int Ophthalmol; 2015 Dec; 35(6):801-6. PubMed ID: 25682013 [TBL] [Abstract][Full Text] [Related]
20. Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. Jelcic I; Hanson JVM; Lukas S; Weber KP; Landau K; Pless M; Reindl M; Weller M; Martin R; Lutterotti A; Schippling S J Neuroophthalmol; 2019 Mar; 39(1):3-7. PubMed ID: 30015656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]